Literature DB >> 28387832

Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn's Disease: What We Have Accomplished and What We Still Need to Do.

Amy L Lightner1, William A Faubion2.   

Abstract

Perianal Crohn's disease [CD] is found in a quarter of patients with CD and remains notoriously difficult to treat. Several medical and surgical therapies are available. However, none is particularly effective nor reliably provides sustained remission. In addition, surgical intervention is complicated by poor healing and the potential for incontinence. Mesenchymal stem cell-based therapies provide a promising treatment alternative for perianal CD, with demonstrated safety, improved efficacy, and a decreased side effect profile. Several phase I, II, and now III randomised controlled trials have now reported safety and efficacy in treating perianal CD. The aim of this review is to discusses the outcomes of conventional treatment approaches, outcomes of mesenchymal stem cell therapies, considerations specific to stem cell-based therapies, and future directions for research.
Copyright © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; Stem cells; perianal fistula

Mesh:

Year:  2017        PMID: 28387832     DOI: 10.1093/ecco-jcc/jjx046

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  8 in total

Review 1.  Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease.

Authors:  Fernando Bermejo; Iván Guerra; Alicia Algaba; Antonio López-Sanromán
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

2.  Management of Fistulas in Patients With Crohn's Disease.

Authors:  Amy L Lightner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-11

Review 3.  Stem cell transplantation for induction of remission in medically refractory Crohn's disease.

Authors:  Sarah El-Nakeep; Ahmed Shawky; Sara F Abbas; Osama Abdel Latif
Journal:  Cochrane Database Syst Rev       Date:  2022-05-13

Review 4.  Neuroinflammation, Bone Marrow Stem Cells, and Chronic Pain.

Authors:  Yul Huh; Ru-Rong Ji; Gang Chen
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

Review 5.  Medical and surgical management of perianal Crohn's disease.

Authors:  Samuel O Adegbola; Anthea Pisani; Kapil Sahnan; Phil Tozer; Pierre Ellul; Janindra Warusavitarne
Journal:  Ann Gastroenterol       Date:  2018-02-08

6.  Cell Therapy With Mesenchymal Stem Cells Induces an Innate Immune Memory Response That Attenuates Experimental Colitis in the Long Term.

Authors:  Mercedes Lopez-Santalla; Rosario Hervas-Salcedo; Maria Fernandez-Garcia; Juan Antonio Bueren; Marina Inmaculada Garin
Journal:  J Crohns Colitis       Date:  2020-10-05       Impact factor: 9.071

7.  Long non-coding RNA SNHG16 promotes human placenta-derived mesenchymal stem cell proliferation capacity through the PI3K/AKT pathway under hypoxia.

Authors:  Xu-Dong Feng; Jia-Hang Zhou; Jun-Yao Chen; Bing Feng; Rui-Tian Hu; Jian Wu; Qiao-Ling Pan; Jin-Feng Yang; Jiong Yu; Hong-Cui Cao
Journal:  World J Stem Cells       Date:  2022-09-26       Impact factor: 5.247

Review 8.  Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.

Authors:  Meng-Yue Shi; Lian Liu; Fu-Yuan Yang
Journal:  World J Stem Cells       Date:  2022-09-26       Impact factor: 5.247

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.